To evaluate the therapeutic potential of targeting DAPK1 to regulate tau SUMOylation in AD-like pathologies, we investigated the effects of pharmacological inhibition of DAPK1 on tau pathology, synaptic plasticity, and cognitive function. This evidence concerns the gene DAPK1 and Alzheimer disease.